SCHEMBL2264759

SCHEMBL2264759

N#Cc1c(C(F)(F)F)cc(-c2ccccc2)n(Cc2cc(F)ccc2F)c1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.71
NR1H2 P55055 3/20 0.71
NR1H3 Q13133 3/20 0.71
KDM4E B2RXH2 13/20 0.45
ALDH1A1 P00352 12/20 0.45
MAPT P10636 3/20 0.45
HPGD P15428 6/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
GAA P10253 5/20 0.43
GLA P06280 3/20 0.43
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
HTT P42858 2/20 0.40
GNRHR P30968 1/20 0.40
L3MBTL1 Q9Y468 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2262731 0.91 RXRA (0.83) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2264570 0.90 RXRA (0.68) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL14214400 0.89 RXRA (0.84) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2263449 0.89 RXRA (0.67) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2260957 0.89 RXRA (0.58) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2266403 0.88 RXRA (0.67) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL4907889 0.87 RXRA (0.68) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2263915 0.87 RXRA (0.65) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL14214340 0.85 RXRA (0.75) RXRANR1H2NR1H3KDM4EALDH1A1
SCHEMBL2265348 0.85 RXRA (0.63) RXRANR1H2NR1H3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465869-B1 MODULATORS OF LXR EXELIXIS PATENT CO LLC (US) 2013-05-15 EP disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 RXRA 16/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.